

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

AN
Claims 1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a disorder characterized by amyloid deposition Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of an agent synuclein or a fragment thereof effective to produce an immune response comprising anti-synuclein antibodies against an amyloid component characteristic of said disorder and an adjuvant that augments the immune response to the synuclein, and thereby preventing or treating the disease.

Claims 12-14: (Canceled)

Claim 15. (Currently Amended) The method of claim 13 11, wherein said amyloid component synuclein or fragment thereof is a is selected from the group consisting of AA, AL, ATTR, AapoA1, Alys, Agel, Acys, A β , AB₂M, ASer, Acal, AIAPP and synuclein-NAC fragment.

Claims 16-17: (Canceled)

Claim 18. (Currently Amended) The method of claim 17 11, wherein said administering includes further comprises administering at least two amyloid fibril components A β or a fragment thereof.

Claim 19. (Currently Amended) The method of claim 11, wherein said agent is a peptide synuclein or fragment thereof is linked to a carrier protein.

Claim 20. (Canceled)

Claim 21. (Currently Amended) The method of claim 2011, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum and ~~Freund's adjuvant~~.

Claim 22. (Currently Amended) The method of claim 11, wherein said immunological immune response is characterized by a serum titer of the anti-synuclein antibodies of at least 1:1000 with respect to said amyloid component A β .

Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the anti-synuclein antibodies is at least 1:5000 with respect to said fibril component A β .

Claim 24. (Currently Amended) The method of claim 11, wherein said immunological immune response is characterized by a serum amount titer of immunoreactivity anti- synuclein antibodies corresponding to greater than about four times higher than a serum level titer of immunoreactivity anti- A β antibodies measured in a pre-treatment control serum sample.

Claim 25. (Original) The method of claim 24, wherein said serum amount of immunoreactivity titer of the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)